Research programme: ramipril formulations - King Pharmaceuticals/Arrow InternationalAlternative Names: ramipril formulations - King/Arrow
Latest Information Update: 03 Mar 2011
At a glance
- Originator Arrow International
- Developer Pfizer
- Mechanism of Action ACE inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Phase Unknown Hypertension
Most Recent Events
- 01 Mar 2011 King Pharmaceuticals has been acquired and merged into Pfizer
- 20 Feb 2006 Investigation in Hypertension in USA (unspecified route)